Brain Tumor Treatment: BI 764532 Dosing Study

We are testing how well different doses of BI 764532 are tolerated by people with brain tumors that are positive for DLL3. This study aims to ensure the safety of the medication for future use.

1-2 yearsSafety phase (I)NeurologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
SCRI CCCIT Ges.m.b.H.
University clinic for internal medicine 3
Salzburg, Austria
Goethe University Frankfurt
Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum der Neurologie und Neurochirurgie
Frankfurt am Main, Germany
Klinikum der Universitaet Muenchen AöR
Neuroonkologisches Zentrum, Comprehensive Cancer Center München
Neuried, Germany

Sponsor: Boehringer Ingelheim International GmbH
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.